JPWO2021168028A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021168028A5 JPWO2021168028A5 JP2022549496A JP2022549496A JPWO2021168028A5 JP WO2021168028 A5 JPWO2021168028 A5 JP WO2021168028A5 JP 2022549496 A JP2022549496 A JP 2022549496A JP 2022549496 A JP2022549496 A JP 2022549496A JP WO2021168028 A5 JPWO2021168028 A5 JP WO2021168028A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- compound
- binds
- administered
- gbq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025207474A JP2026049728A (ja) | 2020-02-18 | 2025-11-28 | Ｐｓｍａ発現がんを処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977932P | 2020-02-18 | 2020-02-18 | |
| US62/977,932 | 2020-02-18 | ||
| PCT/US2021/018447 WO2021168028A1 (en) | 2020-02-18 | 2021-02-18 | Method of treating psma-expressing cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207474A Division JP2026049728A (ja) | 2020-02-18 | 2025-11-28 | Ｐｓｍａ発現がんを処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023514333A JP2023514333A (ja) | 2023-04-05 |
| JP2023514333A5 JP2023514333A5 (https=) | 2024-02-26 |
| JPWO2021168028A5 true JPWO2021168028A5 (https=) | 2024-02-26 |
Family
ID=77391664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549496A Pending JP2023514333A (ja) | 2020-02-18 | 2021-02-18 | Ｐｓｍａ発現がんを処置する方法 |
| JP2025207474A Pending JP2026049728A (ja) | 2020-02-18 | 2025-11-28 | Ｐｓｍａ発現がんを処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207474A Pending JP2026049728A (ja) | 2020-02-18 | 2025-11-28 | Ｐｓｍａ発現がんを処置する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230098279A1 (https=) |
| EP (1) | EP4107279A4 (https=) |
| JP (2) | JP2023514333A (https=) |
| CN (1) | CN115380117A (https=) |
| WO (1) | WO2021168028A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CN118852044A (zh) | 2021-09-03 | 2024-10-29 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4095130T (lt) * | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| US20150110814A1 (en) * | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| EP3607319A1 (en) * | 2017-04-07 | 2020-02-12 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| TW201922291A (zh) * | 2017-11-16 | 2019-06-16 | 瑞士商諾華公司 | 組合療法 |
| SG11202005511VA (en) * | 2017-12-13 | 2020-07-29 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
| US12208102B2 (en) * | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| WO2019246514A1 (en) * | 2018-06-21 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
-
2021
- 2021-02-18 EP EP21757774.1A patent/EP4107279A4/en active Pending
- 2021-02-18 US US17/904,442 patent/US20230098279A1/en active Pending
- 2021-02-18 WO PCT/US2021/018447 patent/WO2021168028A1/en not_active Ceased
- 2021-02-18 CN CN202180029214.XA patent/CN115380117A/zh active Pending
- 2021-02-18 JP JP2022549496A patent/JP2023514333A/ja active Pending
-
2025
- 2025-11-28 JP JP2025207474A patent/JP2026049728A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Corpetti et al. | Prostate-specific membrane antigen–targeted therapies for prostate cancer: towards improving therapeutic outcomes | |
| JP2024178159A5 (https=) | ||
| ligan et al. | 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals | |
| Ricci et al. | Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer | |
| Yoshii et al. | Multiple administrations of 64Cu-ATSM as a novel therapeutic option for glioblastoma: a translational study using mice with xenografts | |
| JP2022501441A5 (https=) | ||
| Liu et al. | Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors | |
| Lee et al. | Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). | |
| JPWO2021168028A5 (https=) | ||
| Davisson et al. | Predictors of survival after yttrium-90 radioembolization of chemotherapy-refractory hepatic metastases from breast cancer | |
| KR20100021403A (ko) | 코발라민 탁산 생체접합체 | |
| Nagy et al. | Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers | |
| Holzleitner et al. | Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy | |
| Liu et al. | Exploring the impact of PEGylation on pharmacokinetics: a size-dependent effect of polyethylene glycol on prostate-specific membrane antigen inhibitors | |
| Zhang et al. | Preclinical evaluation of [211At] At-AuNP-ABDMPL16 for targeted alpha therapy in Melanoma | |
| Chambers et al. | Elevating theranostics: The emergence and promise of radiopharmaceutical cell‐targeting heterodimers in human cancers | |
| Lara Jr et al. | Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial | |
| Tanaka | UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction | |
| Ludwig et al. | SW43-DOX±loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment–An in vitro evaluation | |
| Xu et al. | Synthesis and evaluation of 64Cu-radiolabeled NOTA-cetuximab (64Cu-NOTA-C225) for immuno-PET imaging of EGFR expression | |
| Baranowska-Kortylewicz et al. | Emerging role of platelet-derived growth factor receptor-β inhibition in radioimmunotherapy of experimental pancreatic cancer | |
| KR20260040237A (ko) | Psma 표적 방사성 리간드 치료 요법 | |
| JPWO2020061458A5 (https=) | ||
| Huang et al. | IKS04, a CanAg-Targeting Antibody–Drug Conjugate with Pyrrolobenzodiazepine, Shows Enhanced Efficacy with Unconjugated Antibody Coadministration in Animal Models | |
| Muzammal et al. | Current Status of PSMA-Targeted Agents Based on Small Molecules for Prostate Cancer in Preclinical Studies |